Victor Bulto has been announced as Fabrice Chouragqui’s replacement as Novartis’ company president for its US pharmaceutical business.
Victor is currently the head of the companies US immunology, hepatology and dermatology franchise and has been part of the company for 14 years. Within this time, Victor was involved in the success of Novartis’s psoriasis drug Cosentyx, which saw a 25% growth in the second quarter of 2019.
“Victor Bulto announced as Novartis’ new US pharma president “
Victor will report to Global president Marie France Tschudin, another new member to the leadership team, joining in June 2019.